TAG's October newsletter with articles about the side effects and efficacy of efavirenz (Sustiva) and abacavir (Ziagen), and a report on a meeting at Gallo's lab.
Me-too's Rule: Geneva 'New Agents' Sessions Betray Dearth of Interest in Imaginative (or Costly) Drug Development, Recipe for a Cure: One Part Aged Innovation, Two Parts Hubris: Is Remune Merely Reheated '93 Berlin Fare?, Whither Eradication? Nineteen ninety-six's naïve assumptions, Highlights from the Resistance Workshop (modified 8/20/98)
Vaccine Tug-of-War: Laboratory Purists and Renegade Empiricists Duke It Out Over How to Proceed with Vaccine Development Efforts; Selected HIV Vaccine Approaches (Table); Tantalizing Research Paper Contemplates the Restoration of HIV-Specific 'T-Help' After HAART
Always watch for outdated information. These articles first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. TAGline is published monthly by the Treatment Action Group (TAG), a 501(c)(3) non-profit treatment advocacy organization in New York City. Copyright © 1998 - Treatment Action Group (TAG), 200 East 10th Street, #60, New York, NY 10003, phone: (212) 260-0300, fax: (212) 260-8561. All rights reserved. No part of this publication may be copied or reproduced in any form or by any means without the written permission of Treatment Action Group.